To improve decision making in the treatment of extreme obesity, the risks of bariatric surgical procedures require further characterization.
T he benefits of bariatric surgery are increasingly reported. A recent, small, randomized trial 1 showed that there was a remission of diabetes in a majority of patients who underwent bariatric surgery, and the favorable effect of bariatric surgery on cardiovascular disease was shown in a large, matched cohort of patients who either underwent surgery or received usual care. 2 Recent studies 3, 4 showed that the risk of death over time was approximately 35% lower among extremely obese patients who underwent bariatric surgery than among those who did not. Nevertheless, concern about the safety of bariatric surgery has grown with its increasing popularity and has been heightened by periodic highprofile reports in the lay press of deaths after bariatric surgery and of the closure or threatened suspension of bariatric programs because of safety issues. Malpractice insurers have expressed concern about the increased risk they incur when they provide liability-insurance coverage to bariatric surgeons. Furthermore, some reports suggest that there are higher-than-expected rates of death in high-risk populations undergoing bariatric surgery. 5, 6 Determining the incidence of infrequent adverse outcomes and the factors associated with them requires large prospective cohorts with standardized presurgical evaluation and complete assessment of outcomes. The Longitudinal Assessment of Bariatric Surgery (LABS) consortium conducted a prospective, multicenter, observational cohort study (LABS-1) 7 that used a standardized assessment in consecutive patients undergoing bariatric surgery. This report presents the incidence of, and factors associated with, 30-day safety outcomes in patients from this cohort who underwent an initial bariatric surgical procedure.
Me thods

Patients
The study included consecutive patients 18 years of age or older who underwent bariatric surgical procedures from March 11, 2005 , through December 31, 2007 , performed by 33 LABS-certified surgeons (see the Appendix for a list of centers and the data coordinating center). The study protocol and consent form were approved by the institutional review board at each institution. 7 Surgeons were certified to participate in the LABS-1 study, but bariatric surgical accreditation did not exist when the LABS-1 study began.
By December 31, 2007, a total of 5648 patients had been invited to participate in the study, and 4776 had undergone primary operations. Rouxen-Y gastric bypass was performed either laparoscopically or through an "open" approach; laparoscopic adjustable gastric banding was considered separately. Procedures that started laparoscopically and were converted to open surgery were considered to be open. Procedures that comprised less than 3% of all procedures (biliopancreatic diversion with or without a duodenal switch, sleeve gastrectomy, vertical banded gastroplasty, and open adjustable gastric banding) were excluded from the outcome analyses.
Collection of Data
Details of the preoperative, operative, and postoperative data-collection forms and definitions have been reported previously. 7 The preoperative evaluation was completed by means of an in-person interview, physical examination, and chart review, all of which were conducted by LABS-certified data collectors. Standardized protocols and instruments were used to measure weight, height, and blood pressure within 30 days before surgery. Coexisting conditions were self-reported, and severity was based on the associated use of health care resources (e.g., patients were asked if they had sleep apnea and, if so, whether they used a continuous positive airway pressure machine). The primary outcome was a composite end point of any of the following occurring within 30 days after surgery: death; deep-vein thrombosis or venous thromboembolism; reintervention with the use of percutaneous, endoscopic, or operative techniques; or failure to be discharged from the hospital within 30 days after surgery. We did not consider readmission per se as an adverse event, owing to the variable severity of problems that led to readmission. We did not collect information on insurance status, and research funds were not used to pay for procedures.
Statistical Analysis
Enrollment of patients was dictated by the number of procedures performed by participating surgeons. Before enrollment began, we calculated the number of patients that would be needed for the study to have a power of 90% to detect a doubling in the risk that selected outcome events would occur with various incidences, given the prevalence of several putative risk factors.
Characteristics of the patients who underwent the two bariatric procedures were compared with the use of Pearson's chi-square test for categorical variables and the Kruskal-Wallis test for continuous variables. The incidence of 30-day adverse outcomes was compared among the procedures with the use of Pearson's chi-square test. Generalized linear mixed-effect models were used to evaluate predictors of the composite end point, with the log odds of events modeled as a linear function of baseline covariates. Correlation among patients of the same surgeon was accounted for by the inclusion of different random intercepts for sites and for surgeons within site. Linear and quadratic effects of body-mass index on the composite end point were considered, since the unadjusted analysis showed a quadratic relationship. For multivariable models, a stepwise variable selection was performed, starting with all the variables from univariate models that had a P value of less than 0.25 as potential predictors. Variables were eliminated from the multivariable model if the P value was greater than 0.10, and the process was continued. After the inclusion of main effects that had a P value of less than 0.10, variables that had been considered previously were again included in models to determine whether further adjustment changed the P value of those effects. The final model included only main effects that had a P value of less than 0.10, at which point two-way interactions among all the main effects were evaluated. Predicted probabilities of the composite end point were calculated on the basis of the multivariable model. All P values reported are two-sided.
R esult s
Patients
Of 4776 patients undergoing first-time or "primary" bariatric procedures, the mean (±SD) age was 44.5±11.5 years ( Table 1 ). The median bodymass index (the weight in kilograms divided by the square of the height in meters) was 46.5; 21.1% of the patients were men. The most common procedure was Roux-en-Y gastric bypass, which was performed in 3412 of the patients (71.4%); 87.2% of these procedures were performed laparoscopically and 12.8% with an open surgical technique. A total of 1198 patients (25.1%) underwent laparoscopic adjustable gastric banding; 166 patients (3.5%) underwent other bariatric procedures (Fig. 1) .
Coexisting conditions were common (see Table 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org): 82.1% of the patients had at least one condition, 53.9% had two or more, and 26.5% had three or more. The most common coexisting conditions were hypertension (55.1%), obstructive sleep apnea (48.9%), diabetes (33.2%), and asthma (23.1%). Other relatively less frequent coexisting conditions included ischemic heart disease (4.4%), venous edema with ulcerations (4.0%), a history of deep-vein thrombosis or venous thromboembolism (3.5%), dependence on supplemental oxygen (3.5%), congestive heart failure (2.2%), an inability to walk 61 m (approximately 200 ft) (1.8%), and pulmonary hypertension (1.2%). Preoperative medications that were used by patients included antidepressants (39.9%), statins (26.6%), beta-blockers (17.9%), and narcotics (16.1%).
Patients undergoing open Roux-en-Y gastric bypass, as compared with those undergoing laparoscopic Roux-en-Y gastric bypass or laparoscopic adjustable gastric banding, had a higher median body-mass index (50.9 for open Roux-en-Y gastric bypass, 46.9 for laparoscopic Roux-en-Y gastric bypass, and 44.1 for laparoscopic adjustable gastric banding) and more coexisting conditions (P<0.001 for all comparisons). Patients undergoing open Roux-en-Y gastric bypass generally had the most severe coexisting issues (e.g., insulindependent diabetes and an inability to walk at least 61 m, necessitating assistive devices); patients undergoing either laparoscopic Roux-en-Y gastric bypass or open Roux-en-Y gastric bypass had more coexisting conditions than those undergoing laparoscopic adjustable gastric banding ( Table 1 in the Supplementary Appendix).
Primary Outcome
For the analyses of outcomes, we excluded the 166 patients who underwent operations that are performed relatively rarely, since the putative risks are quite disparate and the frequencies are too small for meaningful analyses (Table 2) . Within 30 days after surgery, 0.3% of the patients had died: none of the 1198 patients who had undergone laparoscopic adjustable gastric banding, 0.2% of the 2975 patients who had undergone laparoscopic Roux-en-Y gastric bypass, and 2.1% of the 437 patients who had undergone open Roux-en-Y gastric bypass.
The composite end point of death, deep-vein thrombosis or venous thromboembolism, reintervention, or failure to be discharged by 30 days after surgery occurred in 4.1% of patients: 1.0% of patients who had undergone laparoscopic ad- 8.3%). The most commonly occurring components of the end point were abdominal reoperation (2.6%) and endoscopic intervention (1.1%). Although the protocol for reporting adverse outcomes included only those events that necessitated reintervention, we collected information on intraoperative events. There was one unplanned splenectomy during a gastric bypass, and three patients underwent a concurrent blood-vessel repair or ligation to control bleeding. Data about the management of postoperative bleeding without reintervention were not collected. Several characteristics of the patients and the procedure types were associated with the composite end point in unadjusted analyses ( Table 2 in the Supplementary Appendix). Owing to interrelationships among several of those variables, after adjustment, only the type of procedure (open and laparoscopic Roux-en-Y gastric bypass, as compared with laparoscopic adjustable gastric banding), extremes of body-mass index, an inability to walk 200 ft, a history of deep-vein thrombosis or venous thromboembolism, and a history of obstructive sleep apnea were significantly associated with the composite end point. After adjustment for specific patient characteristics, the risk of the composite end point with laparoscopic Roux-en-Y gastric bypass, as compared with laparoscopic adjustable gastric banding, was increased by a factor of 4.8; the risk of the composite end point with open Roux-en-Y gastric bypass, as compared with laparoscopic adjustable gastric banding, was increased by a factor of 5.8. After adjustment, there was no significant difference in the odds of the composite end point with open Roux-en-Y gastric bypass, as compared with laparoscopic Roux-en-Y gastric bypass, regardless of whether surgeries in which the laparoscopic approach was converted to the open approach were included (odds ratio for the inclusion of converted approaches, 1.21; 95% confidence interval [CI], 0.71 to 2.04; odds ratio for the exclusion of converted approaches, 1.38; 95% CI, 0.77 to 2.49).
Regardless of the type of procedure, the predicted probability of the composite end point was lowest among patients who did not have a history of deep-vein thrombosis or venous thromboembolism or of obstructive sleep apnea and who were in the middle range of the spectrum of bodymass index for the cohort. apnea or venous thromboembolism and had a body-mass index in the 50s to more than 10% among patients who had a history of deep-vein thrombosis or venous thromboembolism and of obstructive sleep apnea and a body-mass index of 70 (Fig. 2) . Despite higher point estimates for the predicted probability of the composite end point among patients with a body-mass index of less than 53 (the value at which the predicted probability of the composite end point was lowest), the confidence intervals for those estimates are wide; only 13.5% of procedures and 12.2% of events occurred in patients who had a body-mass index of less than 40.
Discussion
In this study, we report major perisurgical adverse outcomes in a recent cohort of patients undergoing the most common bariatric surgical procedures performed by experienced surgeons in established U.S. centers. Despite multiple coexisting conditions in this severely obese population, the overall 30-day mortality (0.3%) and the rate of major adverse outcomes were low. Specific presurgical health conditions and extreme obesity were associated with an increased number of adverse outcomes within 30 days after surgery. These higher-risk characteristics were generally more common among patients undergoing gastric bypass than among those undergoing adjustable banding, but the patients who underwent gastric bypass had a higher risk of adverse events, even after we accounted for these characteristics, and the patients who underwent more invasive procedures also had a higher risk of events. Characteristics of the patients (e.g., male sex, coexisting medical conditions, and a higher bodymass index), of the operation (i.e., degree of invasiveness), of the surgeon, and of the site have been thought to increase the risk of adverse outcomes. Our study provides standardized, prospective data on a cohort from multiple centers that is large enough to evaluate potential factors associated with safety outcomes. Understanding the factors that underlie risk is imperative for developing risk-stratification models that can be used for comparing the outcomes among hospitals and surgeons and for providing the best advice to patients. The complex interplay of factors associated with adverse outcomes represents a challenge in determining a predictive model for risk in bariatric surgery. At least one scoring system of risk that was created from a single-site retrospective cohort has been proposed 8 and has been validated in an alternative cohort 9 ; the variables used in the scoring included age, body-mass index, sex, presence or absence of hypertension, and risk or no risk of venous thromboembolism. Of these factors, only body-mass index and a history of venous thromboembolism were independently associated with the composite end point in our study. Although a higher body-mass index has been shown to increase the risk of an adverse outcome after bypass procedures, 5 our study showed that the body-mass index had a quadratic relationship to the predicted probability of the composite end point. The lowest predicted risk was found at a body-mass index of 53. The risk of the composite end point among patients with a bodymass index of 75 was 61% higher than the risk among those with a body-mass index of 53 (odds ratio, 1.61; 95% CI, 1.04 to 2.48). The predicted risk of the composite end point among patients with a body-mass index of less than 53 was also higher than the risk among those with a bodymass index of 53, but the odds ratio did not differ significantly for any body-mass index below 53.
Although blacks have been reported to lose less weight than whites after bariatric surgery, [10] [11] [12] disparity in the safety outcome has not been rigorously evaluated. Safety outcomes may turn out to be independent of weight-loss outcomes. The experience at the centers in our study may be unique, and perhaps previous studies that showed differences in outcomes according to race did not adequately control for the relationship between race and other factors. Furthermore, the statistical power to disentangle race from other confounding factors may be inadequate in our study, since only 10.9% of the patients were nonwhite. Although older age has been associated in many studies 6, 13, 14 with an increased likelihood of adverse outcomes, age was not significantly associated with outcome in our study. This finding may be explained in part either by the relatively small number of older patients (more than half the patients were in their 30s or 40s) or by a preferential selection of relatively healthy patients. In our study, older patients had, on average, a lower bodymass index than younger patients. 15 A recent single-surgeon report of 1000 Roux-en-Y gastric bypass procedures showed that obstructive sleep apnea conferred a risk of perioperative death that When a choice must be made among different bariatric procedures, short-term safety may not be the only relevant factor. Laparoscopic adjustable gastric banding and laparoscopic Roux-en-Y gastric bypass have different effects on weight and obesity-related conditions. In most patients, Roux-en-Y gastric bypass affects glycemic control even before weight loss occurs, 17 whereas the effects of laparoscopic adjustable gastric banding are dependent on weight loss. 1, 18 Data concerning the effectiveness of the procedures and the durability of their effects are critical. 19,20 Although our study was designed to evaluate short-term safety events, LABS-2 (ClinicalTrials.gov number 00465829), a long-term, prospective cohort evaluation that has just finished recruitment, is designed to assess the effect of these operations on health conditions, quality of life, health economic issues, diet and exercise behavior, and other psychosocial issues.
Our study had several limitations, which have been noted previously 17 and are summarized here. Whether our findings would be replicated in the general community is unknown. Recent data from administrative databases have shown that in-hospital outcomes after bypass surgery have improved since the 1990s. 21, 22 Owing to Center of Excellence programs and formal training programs, we anticipate that the low rates of perioperative death and adverse outcomes seen in LABS centers will be achievable elsewhere. Since our study was large, multicenter, and prospective, some of the subgroups of patients were large; however, the limited size of other patient subgroups may have resulted in a type II error that did not identify a difference in safety among groups. Although we found expected differences in the rates of safety events among procedures on the basis of the degree of invasiveness, between-procedure comparisons on the basis of a common safety metric may not be appropriate. Some adverse outcomes are expected to occur only in the case of certain procedures (e.g., leaks of gastrointestinal anastomoses are a risk in Roux-en-Y gastric bypass but not in laparoscopic adjustable gastric banding), so a common metric that includes reoperation is biased against procedures with anastomoses. An additional limitation was that the preoperative existence and severity of conditions was determined by patients' self-report. Finally, although the case volume of a particular center or surgeon is worthwhile to document in evaluating outcomes, we could not determine the case volume at the centers, because at some centers not all surgeons participated in the LABS consortium, and surgeons in the LABS consortium were certified by the consortium to participate at various times during the year. Thus, the actual surgical volume for that year may not have been captured. The multivariable analysis was adjusted for center but not explicitly for center volume.
Obesity remains a major cause of illness and death, and bariatric surgery appears to be the only intervention that consistently results in substantial, sustained weight loss. The safety of such surgery is an important consideration, and our study shows that the incidence of death and adverse events within 30 days after bariatric surgery is low but is varied among different risk groups. These short-term risks should be considered in the context of the long-term health effects of surgically induced weight loss on coexisting health conditions, the long-term risks of the bariatric surgery itself, the competing risk of death from extreme obesity, and the relative benefits of the rate and durability of weight loss.
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